Ignite Creation Date:
2024-05-05 @ 10:18 PM
Last Modification Date:
2024-10-26 @ 10:16 AM
Study NCT ID:
NCT01072591
Status:
TERMINATED
Last Update Posted:
2013-01-29
First Post:
2010-02-19
Brief Title:
Study to Assess MEDI -578 in Patients With Osteoarthritis OA of the Knee
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Phase I Double-blind Randomised Placebo-controlled Parallel-group Study to Assess SafetyTolerability Pharmacokinetics and Efficacy of MEDI-578 an Anti-NGF Monoclonal Antibody After Single Ascending Doses in Male and Non-fertile Female Patients With Painful Osteoarthritis of the Knee
Status:
TERMINATED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Amended clinical development plan
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety and tolerability of a single intravenous dose of MEDI-578 a monoclonal antibody in patients with osteoarthritis of the knee It will also be evaluated how MEDI-578 is absorbed and distributed through the body
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None